- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Lung Cancer | Clinical
Pralsetinib Shows Positive Phase 1/2 Results in RET Fusion+ NSCLC
November 26, 2022
Updated analysis from the phase 1/2 ARROW study evaluating pralsetinib in patients with RET fusion-positive non–small cell lung cancer showed the agent to be well tolerated and to elicit clinical activity at a dose of 400 mg daily.
Case 1: Metastatic NSCLC with an EGFR Exon 20 Insertion
November 25, 2022
Joel Neal, MD, PhD, presents the case of a 66-year-old woman with no smoking history and a diagnosis of EGFR exon 20 mutation-positive mNSCLC.
Common Biomarker Testing Methodologies Utilized in NSCLC
November 25, 2022
Zosia Piotrowska, MD, explains molecular testing methods that can discover molecular alterations in common biomarkers in patients with mNSCLC.
Update Confirms 5-Year Survival Benefit With Dual Immune Checkpoint Blockade in NSCLC
November 24, 2022
A 5-year survival update of CheckMate 227 support the use of nivolumab plus ipilimumab in patients with advanced non–small cell lung cancer.
Lung Cancer Awareness Month: New Targeted Therapy Options in Advanced NSCLC
November 23, 2022
Surabhi Pathak, MD, reviews current and upcoming targeted treatments in patients with non–small cell lung cancer for Lung Cancer Awareness Month.
Nadler Reviews Targeted Therapy for EGFR Exon 20 Insertion NSCLC
November 21, 2022
During a Targeted Oncology case-based roundtable event, Eric S. Nadler, MD, MPP, discussed the data supporting the use of targeted therapy for patients with non–small cell lung cancer and an EGFR exon 20 insertion.
Frontline Nivolumab/Ipilimumab + Chemotherapy Benefit Extends to Histology and PD-L1 Subgroups in mNSCLC
November 19, 2022
Updated data from the phase 3 CheckMate 9LA trial showed that the combination of nivolumab, ipilimumab, and 2 cycles of chemotherapy elicited survival benefit in patients with treatment-naïve metastatic non–small cell lung cancer.
Cemiplimab Makes Case as First-Line, Nonchemotherapy Treatment in Metastatic NSCLC
November 18, 2022
Updated results of the EMPOWER-Lung1 trial of cemiplimab in patients advanced or metastatic non–small cell lung cancer showed improvements in overall survival, progression-free survival, and overall response rate.
Tepotinib Demonstrates Durable Benefit With High-Level MET Amplification
November 17, 2022
Tepotinib was able to provide clinically meaningful activity in patients with high MET amplification non–small cell lung cancer in the VISION study, according to Xiuning Le, MD, PhD.
Reflex Testing of Next Generation Sequencing (NGS)-Based Panels in NSCLC
November 17, 2022
Nurse Practitioner Lauren Welch and Dr Michelle Shiller share whether next-generation sequencing is reflexively ordered at their institutions, turnaround times for this type of testing, and which panels they typically choose.